EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis

Lutfi Cagatay Onar iD, Ersin Guner iD, Irem Ozten Dalkiran, Ibrahim Yilmaz iD

Medical Sciences · 19.05.2026 · 14 (2) · 260

DOI: 10.3390/medsci14020260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 19.05.2026. Verfasst von Lutfi Cagatay Onar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Dr. Ismail Fehmi Cumalioglu City Hospital, Republic of Turkey Ministry of Health, Tekirdag 59020, Turkey. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Venous Thromboembolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venous thromboembolism (VTE) is a thromboinflammatory disorder involving coordinated activation of coagulation, endothelial dysfunction, and inflammatory signaling. Low-molecular-weight heparins (LMWHs) may exert pharmacological effects beyond anticoagulation. This study compared enoxaparin, bemiparin, and tinzaparin and explored potential multi-target mechanisms using molecular docking, network pharmacology, and enrichment analyses.

Methods

In this retrospective cohort study, patients with acute VTE treated with therapeutic-dose LMWHs were analyzed. Stabilized IPTW based on multinomial propensity scores was used to reduce baseline imbalance between treatment groups. Clinical recovery was assessed using the Clinical Severity Score (CSS). Thromboinflammatory biomarkers (MPV, hs-CRP, NLR, fibrinogen) were evaluated during follow-up. Molecular docking, STRING/Cytoscape-based protein–protein interaction, and enrichment analyses were performed.

Results

Median time to symptom resolution was 31 days with enoxaparin, 28 days with bemiparin, and 24 days with tinzaparin (log-rank p < 0.001). Recovery was faster with bemiparin (HR 1.28, 95% CI 1.05–1.56) and tinzaparin (HR 1.72, 95% CI 1.41–2.10). Tinzaparin showed greater reductions in hs-CRP, MPV, NLR, and fibrinogen (all p < 0.05) and less analgesic use beyond 10 days (19.7% vs. 27.0% and 33.2%; p < 0.001). Docking analyses identified plausible conformations (root-mean-square deviation, RMSD ≤ 2 Å). Given the structural flexibility and heterogeneous chain length of LMWHs, rigid docking algorithms may not fully capture biologically relevant conformations. Therefore, docking results should be interpreted as qualitative interaction mapping rather than quantitative binding affinity estimation. Network analysis highlighted F3, TNF, IL6, and VWF, while enrichment analyses suggested involvement of cytokine signaling, leukocyte migration, and thromboinflammatory pathways.

Conclusions

LMWH therapy was associated with improved thromboinflammatory markers and clinical recovery, with tinzaparin showing comparatively more favorable thromboinflammatory biomarker trajectories and recovery dynamics within the limitations of this observational analysis. Integrated clinical and in silico findings provide hypothesis-generating insights into potential multi-target pharmacological effects beyond anticoagulation; however, these observations should be interpreted cautiously and require experimental validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heparin, Low-Molecular-WeightVenous ThromboembolismHumansFemaleMolecular Docking SimulationRetrospective StudiesEnoxaparinMaleMiddle AgedTinzaparinAgedAnticoagulantsComputer SimulationBiomarkers

Stichwörter der Autor:innen

disease enrichmentlow-molecular-weight heparinmolecular dockingnetwork pharmacologyprotein–protein interactionthromboinflammationtinzaparinvenous thromboembolism

Substanzen

Heparin, Low-Molecular-WeightEnoxaparinTinzaparinbemiparinAnticoagulantsBiomarkers

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Dr. Ismail Fehmi Cumalioglu City Hospital, Republic of Turkey Ministry of Health, Tekirdag 59020, Turkey.
  • Department of Pharmacy, Konya Numune Hospital, Republic of Turkey Ministry of Health, Konya 42060, Turkey.
  • Department of Midwifery, University of Health Sciences, Istanbul 34668, Turkey.
  • Unit of Pharmacovigilance, Dr. Ismail Fehmi Cumalioglu City Hospital, Republic of Turkey Ministry of Health, Tekirdag 59020, Turkey.

ORCID-Profile: Lutfi Cagatay Onar, Ersin Guner, Ibrahim Yilmaz

Zitieren

APA

Onar, L. C., Guner, E., Dalkiran, I. O., & Yilmaz, I. (2026). Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis. Medical Sciences, 14(2), 260. https://doi.org/10.3390/medsci14020260

Vancouver

Onar LC, Guner E, Dalkiran IO, Yilmaz I. Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis. Medical Sciences. 2026;14(2):260. doi:10.3390/medsci14020260

BibTeX
@article{Onar2026,
  author = {Onar, Lutfi Cagatay and Guner, Ersin and Dalkiran, Irem Ozten and Yilmaz, Ibrahim},
  title = {Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {260},
  doi = {10.3390/medsci14020260}
}
Kostenlos starten →